Matinas BioPharma Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Schedule of Components of Accumulated Other Comprehensive Income (Details)

Schedule of Components of Accumulated Other Comprehensive Income (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Equity [Abstract]
Net Unrealized Gains (Losses) on Available-for-Sale Securities, Beginning Balance	$ 228,000	$ 1,000
Accumulated Other Comprehensive (Loss)/Gain, Beginning Balance	228,172	1,000
Net Unrealized Gains (Losses) on Available-for-Sale Securities, Net unrealized loss on securities available-for-sale	(92,000)	523,000
Accumulated Other Comprehensive (Loss)/Gain, Net unrealized loss on securities available-for-sale	(92,000)	523,000
Net Unrealized Gains (Losses) on Available-for-Sale Securities, Other comprehensive income (loss)	(92,000)	523,000
Accumulated Other Comprehensive (Loss)/Gain, Other comprehensive gain	(92,000)	523,000
Net Unrealized Gains (Losses) on Available-for-Sale Securities, Ending Balance	136,000	522,000
Accumulated Other Comprehensive (Loss)/Gain, Ending Balance	136,406	522,000
Net Unrealized Gains (Losses) on Available-for-Sale Securities, Beginning Balance	(228,000)	(1,000)
Accumulated Other Comprehensive (Loss)/Gain, Beginning Balance	$ (228,172)	$ (1,000)

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References + Details